The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
ACADEMIA
Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
After the reimbursement listing of Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) as Japan’s first obesity drug in three decades, the Japan Society for the Study of Obesity (JASSO) released a statement on November 27 urging doctors to use caution…
To read the full story
Related Article
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
- Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
November 16, 2023
- Novo’s Obesity Med Wegovy Skips Listing Again in August
August 24, 2023
- Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
- Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
- Novo Mum over Pass on Wegovy Listing in May
May 19, 2023
- Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
May 17, 2023
- Wegovy First Med to Meet Guidelines Criteria for Obesity Drug Development
March 30, 2023
- Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
- Japan Approves Wegovy, Omvoh, FluMist, Entyvio SC and More
March 28, 2023
ACADEMIA
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…